Aptar Pharma to showcase an industry first

12 Sep 2018

PureHale is a new portable drug delivery device designed for upper respiratory care.

Aptar Pharma will showcase an industry first with its PureHale device – a new portable drug delivery device designed for upper respiratory care - at CPhI Worldwide this year in Madrid.

Aptar Pharma to showcase an industry first

In addition to PureHale, Aptar Pharma will also reveal:

  • A range of new connected drug delivery devices designed to help increase dose adherence and improve patient health outcomes
  • A portfolio of gamma-sterilized drug delivery components to reduce bioburden
  • Aptar Pharma’s Support Services initiative, a portfolio of stage-specific development packages to help customers in their journey from molecule to market.
  • “Through a wide range of consulting and services, Aptar Pharma innovates around delivery routes, effective drug delivery, testing and regulatory requirements with partners ranging from small-scale R&D firms to the largest international pharmaceutical companies. We look forward to launching our Support Services initiative at CPhI, and working with our customers to meet their development needs, said Guillaume Brouet, Vice President Analytical, Regulatory and Scientific Affairs at Aptar Pharma.”

    Along with showcasing its range of innovative drug delivery devices that address nasal, pulmonary, eye care, injectables and dermal drug delivery routes at Aptar Pharma’s exhibit stand, the company will also be sharing various new solutions in prescription and over-the-counter treatments.

    Furthermore, Aptar Pharma executives will be delivering three Pharma Insight Briefings outlining the latest trends, technology and product innovations:

    “Debunking the leachable myths of gamma sterilization: A migration study of steam vs gamma”

    Julie D. Suman, President of Next Breath, a division of Aptar Pharma, Tuesday 9 October, 11:50-12:20.

    Julie Suman will present a migration study commissioned by Aptar Pharma to assess the impact of both steam sterilization and gamma sterilization on leachable profiles.

    “Portable care for your respiratory tract: Exploring new technology platforms”

    Guenter Nadler, Director Business Development, Aptar Pharma, Tuesday 9 October, 12:30-13:00

    Guenter Nadler will discuss new trends in treating upper respiratory tract issues naturally, including new respiratory technology platforms that will meet new market needs.

    “Building a connected devices eco-system for digital medicines”

    Sai Shankar, Director Business Development, Aptar Pharma Wednesday 10 October, 13:50-14:20.

    Sai Shankar will highlight the need for a digital medicine eco-system to ensure connected devices are fully optimised through patient-centric design, secure data collection and management, and cross-platform interoperability.

    Read More

    Related news

    Concept Life Sciences extends GLP accreditation to support regulatory studies

    Concept Life Sciences extends GLP accreditation to support regulatory studies

    10 Nov 2018

    Accreditation ensures quality and integrity of non-clinical laboratory studies to support pharmaceutical and biotech industries.

    Read more 
    Sartorius receives award for outstanding performance in its production chain

    Sartorius receives award for outstanding performance in its production chain

    8 Nov 2018

    Company's manufacturing building for laboratory instruments in Göttingen wins the Global Excellence in Operations Award.

    Read more 
    Record growth at The Wasdell Group

    Record growth at The Wasdell Group

    7 Nov 2018

    Despite Brexit looming, the company's EU & UK business has increased by almost 30% in the last 12 months.

    Read more 
    bioLIVE to merge with BioProduction Congress for 2019 event

    bioLIVE to merge with BioProduction Congress for 2019 event

    7 Nov 2018

    BioProduction’s content platform will be added to the bioLIVE exhibition, creating one of the world’s largest event hubs for the bio industry.

    Read more 
    Proprietary nasal delivery formulation of diazepam reaches NDA

    Proprietary nasal delivery formulation of diazepam reaches NDA

    7 Nov 2018

    The absolute bioavailability of the Valtoco intranasal formulation was 96% of intravenous diazepam in a Phase I cross-over trial.

    Read more 
    Croda opens its Centre of Innovation for marine biotechnology

    Croda opens its Centre of Innovation for marine biotechnology

    5 Nov 2018

    The new Centre of Innovation for Marine Biotechnology will accelerate the company’s research and product development program to identify sustainable, natural sources of functional ingredients.

    Read more 
    Plasticell receives EU funding to advance neurodegenerative disease research

    Plasticell receives EU funding to advance neurodegenerative disease research

    1 Nov 2018

    Th company's CombiCult combinatorial cell culture technology will be used to generate high fidelity, progenitor and terminally differentiated neuronal and glial cell subtypes for incorporation into next-generation models.

    Read more 
    DSCSA one-month countdown!

    DSCSA one-month countdown!

    30 Oct 2018

    With only a month to go, it really is too late to start trying to develop an in-house solution.

    Read more 
    Lonza acquires controlling stake in Octane Biotech to further develop Cocoon autologous technology

    Lonza acquires controlling stake in Octane Biotech to further develop Cocoon autologous technology

    30 Oct 2018

    Acquisition further strengthens Lonza’s commitment to drive the next generation of manufacturing patient-specific and personalized therapies.

    Read more 
    Elpis Biomed human cell models could potentially replace animal experiments in drug discovery

    Elpis Biomed human cell models could potentially replace animal experiments in drug discovery

    28 Oct 2018

    OPTi-OX technology allows the company to produce human cells of unprecedented quality, purity, and consistency.

    Read more